glp 1 and heart rate Glucagon-like peptide receptor agonists: cardiovascular benefits mechanisms of action JCI - Cardioprotective GLP-1 metabolite

That projection starts with first half 2025 semaglutide sales of about $16.4 billion (Ozempic about $9.4 billion, Wegovy roughly $5.4 billion, Rybelsus about $1.7 billion), annualizes that run rate to approximately $33 billion for full-year 2025, and incorporates Novos statement that recent U.S

Wegovy (semaglutide): 7% of adults taking the 2.4 mg dose, and 4% of pediatric patients 12 years and older taking the 2.4 mg dose

However, as research flourishes, patients often ask about other uses of GLP1s, such as neuroprotection or substance use disorders

By targeting both pathways at once, Tirzepatide produces a more comprehensive metabolic effect than GLP-1 alone

A diet high in protein and fiber coupled with ample hydration and consistent resistance training is crucial." Semaglutide is also available with a higher dose (2.4 mg) in the drug Wegovy, which is FDA-approved for weight loss